Complement
Complement Factor B Inhibitor
Ciprocopan is a small molecule for oral, once daily administration that inhibits Factor B, a critical protease within the alternative pathway of the complement cascade. Factor B is a validated target in several complement-mediated diseases.
Oncology
Paradox Breaker BRAF Inhibitor
NXP200 is an oral small-molecule, paradox breaker BRAF inhibitor. It is designed to block the BRAF pathway without triggering the paradoxical activation seen with first-generation BRAF inhibitors.
Oncology
SRC/YES1 Kinase Inhibitor
NXP900 is an oral small-molecule inhibitor targeting the SRC Family of Kinases (SFKs), with low nanomolar potency for SRC and YES1. It blocks both the catalytic activity and the scaffolding functions of the kinase.
